Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of systemic lupus erythematosus for at least 6 months.~* Documentation of at least one of the following: ANA titer \>= 1:160 or positive anti-dsDNA antibodies.~* Stable systemic lupus erythematosus medication regimen.~* Other than systemic lupus erythematosus, subject should be in general good health.~Exclusion Criteria:~* Male.~* Drug-induced or highly active systemic lupus erythematosus.~* Significant autoimmune disease other than lupus.~* Significant, uncontrolled or unstable disease in any organ.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Dose (Type: EXPERIMENTAL): Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
- Multiple Dose (Type: EXPERIMENTAL): Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)

Based on this trial design, predict the completion outcome and termination type (if applicable).